New treatment approach for non-small cell lung cancer using nano-immunotherapy
Official title: Novel Nano-immunotherapy for Treatment of Non-small Cell Lung Cancer
Funded at Pdx Pharmaceuticals, INC. · NIH-10792640 · Data updated 2026-11-12
This study is testing a new treatment called ARAC that uses tiny particles to help boost the power of current therapies for non-small cell lung cancer, aiming to make them work better and improve survival for patients.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Pdx Pharmaceuticals, INC. NIH-funded |
| Lab location | 1 site (Portland, UNITED STATES) |
| Project start | September 23, 2021 |
| Project end | November 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $932,751 |
| NIH project number | 5R44CA265751-03 |
| Project ID | NIH-10792640 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with non-small cell lung cancer who have not responded adequately to existing treatments.
✕Less likely to help
Patients with other types of lung cancer or those who are not eligible for immunotherapy may not benefit from this research.
What this research studies
This research focuses on developing a novel nano-immunotherapy called ARAC, which aims to enhance the effectiveness of existing immune checkpoint inhibitors for treating non-small cell lung cancer (NSCLC). The approach involves creating nanoparticles that can deliver multiple therapeutic agents directly to cancer cells, improving the chances of a curative outcome. By combining a targeted cancer therapy, an immune checkpoint inhibitor, and an immune stimulant, this treatment seeks to overcome the limitations of current therapies and improve patient survival rates.
Why it matters
Potential benefit: If successful, this research could significantly improve treatment outcomes and survival rates for patients with non-small cell lung cancer.
How similar studies have gone: Previous research has shown promise in using nanoparticle-based therapies for cancer treatment, indicating potential success for this novel approach.
Where this research is happening
-
Pdx Pharmaceuticals, INC.
Portland, United States Active
Researchers
- Principal investigator: Ngamcherdtrakul, Worapol — Pdx Pharmaceuticals, INC.
- Study coordinator: Ngamcherdtrakul, Worapol
Related research
Other NIH-funded projects on the same topics.
-
Targeting GARP-TGFβ to Improve Immunotherapy in NSCLC
A new antibody approach aims to block a key TGFβ-related pathway in the tumor environment to help people with non-small cell lung cancer respond better to therapy.
-
Targeting DHX9 to boost viral-like immune response in Small Cell Lung Cancer
A scientist team is testing whether blocking a protein called DHX9 can make aggressive small cell lung cancer more visible to the immune system and more responsive to immunotherapy.
-
Integrated blood and radiomics to guide immunotherapy in metastatic NSCLC
A research project aims to use blood tests and advanced imaging patterns to personalize first-line immunotherapy choices for people with metastatic non-small cell lung cancer.
-
Blocking a tumor pathway to boost immunotherapy for non-small cell lung cancer
This project will see if adding a drug that blocks the Hedgehog pathway to immune checkpoint therapy helps people with non-small cell lung cancer by restoring the immune system's CD8 T cells inside tumors.
-
Improving Immunotherapy for Lung Cancer with CT Scans
This work aims to find new ways to predict which non-small cell lung cancer patients will respond best to immunotherapy using information from their routine CT scans.
-
Using CT scans and patient tests to predict who will benefit from PD‑1 immunotherapy
A computer tool combines CT scan features, blood and tumor markers, and clinical data to predict which people with advanced lung or bladder cancer are likely to benefit from PD‑1 immunotherapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.